EXPLORE!

FDA Approves Galderma's IL-31 Inhibitor Nemluvio to Treat Prurigo Nodularis in Adults

  434 Views

Emedinexus    26 August 2024

The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) to treat adults with prurigo nodularis.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.